{"prompt": "['Trelagliptin-4002', 'Page 27 of 66', 'Version 1.0', 'November 2, 2016', '1.', 'Patients who are receiving any oral anti-diabetic medication for the treatment of type 2', 'diabetes at the start of the screening period.', '2.', 'Patients diagnosed as type 1 diabetes.', '3. Patients with severe renal impairment or renal failure (e.g., eGFR <30 mL/min/1.73 m\u00b2 or on', 'dialysis).', '4.', 'Patients with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or', 'other disease.', '5. Patients with a history of gastrointestinal resection.', '6. Patient with a proliferative diabetic retinopathy.', '7. Patient with malignancy.', '8. Patients with a history of hypersensitivity or allergy to DPP-4 inhibitors.', '9.', 'Pregnant, lactating or postmenopausal women.', '10. Patients who may need to add or discontinue concomitant medication or change the dose', 'during the study period.', '11. Patients who will require treatment with a prohibited concomitant medication during the study', 'period.', '12. Patients participating in other clinical studies.', '13. Patients assessed ineligible in the study by the principal investigator or the investigator.', '[Rationale for the exclusion criteria]', '1, 10: These were set to exclude influences on senses of burden against treatment using', 'concomitant medications including diabetic medications other than the allocated oral', 'glucose-lowering medication.', '2:', 'This was set to exclude patients with type 1 diabetes, because the indications of', 'trelagliptin and daily DPP-4 inhibitors are for \"type 2 diabetes.\"', '3:', 'This was set to exclude patients with severe renal dysfunction or renal failure, because', 'trelagliptin is contraindicated in such patients.', '4-8, 11: These were set in consideration of patient safety.', '9:', 'This was set because trelagliptin should not be administered in pregnant or possibly', 'pregnant females unless potential therapeutic benefits outweigh risks, and because', 'excretion of trelagliptin and alogliptin into milk was observed in the non-clinical studies.', '12,13: These were set as fundamentals for this study.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 28 of 66', 'Version 1.0', 'November 2, 2016', '7.3', 'Prohibited concomitant drugs and permitted concomitant drugs', 'The use of diabetic medications other than allocated oral glucose-lowering medication will', 'be prohibited during from the start of the screening period (Week -4) until the end of the', 'treatment period (Week 12).', '<Rationale of prohibited concomitant drugs>', 'It was designed due to potential influences on the assessment of this clinical study.', '7.4', 'Study subject management', 'The principal investigator and investigator shall instruct the research subject the items below.', '(1) Give instructions to take allocated oral hypoglycemic drug as directed.', '(2)', 'If hypoglycemia symptom (hunger abnormal, feeling of weakness, trembling of hands and', 'fingers, cold sweat, palpitations, etc.) is observed, take glucose or sucrose (sugar), and if it does', 'not improve give instructions to visit promptly.', '(3)', 'On visit days for planned laboratory tests, give instructions not to take oral hypoglycemic drug', 'scheduled to be taken on that day. Further, at each visit, have the research subject report if drug', 'has been taken or not the day before, and on the day of visit.', '(4) On visit days for planned laboratory tests, give instructions for fasting > 10 hours before visit.', '(5) For research subjects of childbearing potential, give instructions to use adequate contraception.', 'If pregnancy is discovered, have the research subject report promptly, and discontinue the', 'research immediately.', '(6)', 'The principal investigator and investigator shall instruct the research subject to adhere to', 'instructed prohibited concomitant drugs. When drugs are taken other than the drugs prescribed', 'by the principal investigator and investigator, have the research subject report its content.', '(7) Regarding subjective symptoms/objective findings, have the research subject report at visit the', 'necessary items from its contents, onset date, degree, outcome and date of outcome.', '7.5', 'Criteria for discontinuation or withdrawal of a study subject', 'The principal investigator or investigator shall record the main reason for discontinuation of protocol', 'treatment on the case report form (CRF) according to the classification described below. Refer to', 'Section 9.1.15 for study subjects who withdraw from the study before randomization.', '1. Adverse events', 'When the study subject had an adverse event that requires withdrawal of the study subject from', 'the study because continued participation in the study would impose an unacceptable risk to the', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}